Invest now
Akums Drugs and Pharmaceuticals share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹749.45(-0.35%)October 13, 2026 12:58:51 PM IST
- NSE
- BSE
- Vol : 79.42 K (NSE + BSE)Last 20 day avg : 283.63 K
Akums Drugs and Pharmaceuticals is trading -0.35% lower at Rs 749.45 as compared to its last closing price. Akums Drugs and Pharmaceuticals has been trading in the price range of 755.25 & 735.00. Akums Drugs and Pharmaceuticals has given 66.26% in this year & -6.23% in the last 5 days. Akums Drugs and Pharmaceuticals has TTM P/E ratio 32.61 as compared to the sector P/E of 44.94.There are 3 analysts who have initiated coverage on Akums Drugs and Pharmaceuticals. There are 2 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 100.01 Crores in its last quarter.Listed peers of Akums Drugs and Pharmaceuticals include Sun Pharmaceutical Industries (0.05%), Divi's Laboratories (-1.90%), Torrent Pharmaceuticals (-1.31%).The Mutual Fund holding in Akums Drugs and Pharmaceuticals was at 7.58% in 30 Sep 2026. The MF holding has decreased from the last quarter. The FII holding in Akums Drugs and Pharmaceuticals was at 4.50% in 30 Sep 2026. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 13 Oct 2026, 01:08 PM IST
- Debt To EquityIn line with industry0.05The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.13Annual dividends as a percentage of the stock price.
- PEG RatioIndicates undervaluation0.98The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- Beta-Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Akums Drugs and Pharmaceuticals News
Akums Drugs and Pharmaceuticals Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,760.00 | 0.05 | 4,22,273.00 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 9,201.00 | -1.90 | 2,44,257.64 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 4,617.55 | -1.31 | 1,75,630.48 | 72.73 | 19.22 | 0.80 | 141.16 |
| Cipla | 1,324.40 | 0.81 | 1,06,992.77 | 27.57 | 3.33 | 0.92 | 1.11 |
| Zydus Lifesciences | 1,130.00 | -0.79 | 1,12,717.93 | 21.19 | 4.24 | 0.09 | 14.22 |
Mutual Fund Ownership
View allAkums Drugs and Pharmaceuticals Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-08-08 | Quarterly Results |
| 2026-05-14 | Audited Results & Final Dividend |
| 2026-02-13 | Quarterly Results |
| 2025-11-13 | Quarterly Results |
| 2025-08-08 | Quarterly Results |
About the company Akums Drugs and Pharmaceuticals
- IndustryBiotechnology & Drugs
- ISININE09XN01023
- BSE Code544222
- NSE CodeAKUMS
Akums Drugs and Pharmaceuticals Limited is an India-based pharmaceutical contract development and manufacturing company. The Company offers a comprehensive range of pharmaceutical products and services in India and overseas. The Company’s segments include Contract Development and Manufacturing Operations (CDMO), Active Pharmaceutical Ingredient (API), Domestic Branded Formulations, International Branded Formulations, and Trade Generics. The CDMO segment is engaged in formulation research and development, preparation and regulatory filing of dossiers, manufacturing formulations on a contract basis, job work and testing services. The API segment is engaged in the manufacture and sale of key starting materials, Intermediate and API products. The Domestic Branded Formulations segment includes marketing of its branded formulations in the Indian market. The International Branded Formulations segment undertakes the marketing of its branded formulations in the global market.
Akums Drugs and Pharmaceuticals Share Price FAQs
Akums Drugs and Pharmaceuticals is trading at 749.45 as on Tue Oct 13 2026 07:28:51. This is -0.35% lower as compared to its previous closing price of 752.10.
The market capitalization of Akums Drugs and Pharmaceuticals is 11795.89 Cr as on Tue Oct 13 2026 07:28:51.
The average broker rating on Akums Drugs and Pharmaceuticals is Strong Buy. The breakup of analyst rating is given below -
- 2 analysts have given a strong buy rating
- 1 analysts have given a buy rating
- 0.00 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Akums Drugs and Pharmaceuticals is 839.25 whereas the 52 wk low is 408.81
Akums Drugs and Pharmaceuticals can be analyzed on the following key metrics -
- TTM P/E: 32.61
- Sector P/E: 44.94
- Dividend Yield: 0.13%
- D/E ratio: -
Akums Drugs and Pharmaceuticals reported a net profit of 255.19 Cr in 2026.
The Mutual Fund Shareholding was 7.58% at the end of 30 Sep 2026.
Quick Links
EQUITY QUICK LINKS
Akums Drugs and Pharmaceuticals QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.